The father of one of two young girls killed and buried in suitcases in Collinwood, Ohio told Nexstar’s WJW Thursday that he ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

Mila Beauté’s cofounder and CEO, Sachin Chadha, shared how the company is making accessible and affordable colour cosmetics without compromising on quality With over 10,000 retail counters across 300 ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Novo Nordisk, maker of Wegovy, saw its stock rise 6.5% after the opening bell on Monday. The company and the U.S. Food and Drug Administration threatened legal action against Hims & Hers, over its ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...